The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1263 articles
Amanda Bynes revealed a striking new tattoo following her 30-pound weight loss with Ozempic. The actress, known for Hairspray and She's the Man, added to her collection at Atomic Tattoo in Hollywood. Her ink symbolizes transformation and friendship amid GLP-1 success.
Ozempic, originally for diabetes, has sparked a cultural shift toward extreme thinness as the new beauty ideal. This rapid reversal from body positivity creates intense social pressures and physical risks like muscle loss. Understand the implications for body image and long-term health.
Kylie Jenner promoted pomegranate-flavored Cutting Jelly as a digestion and debloating aid in a January 10 TikTok video. Dubbed 'Korean Ozempic,' the product drew sharp criticism for irresponsible endorsement. Fans question its safety compared to proven GLP-1 medications.
Semaglutide, a powerful GLP-1 receptor agonist, transforms obesity and diabetes management but requires robust insurance coverage to deliver full benefits. Gasoyan and Rothberg emphasize access hurdles like prior authorizations that delay treatment. Addressing these ensures equitable health improvements amid rising metabolic disorders.
A scientific review identifies green tea and other dietary compounds that could replicate GLP-1 inhibitor effects for weight management. Researchers from Heliopolis University highlight potential natural alternatives amid high medication costs and side effects. Experts caution these are not direct substitutes.
Novo Nordisk ramps up direct-to-consumer access to its new daily Wegovy pill through NovoCare's redesign and telehealth ties. Berenberg analysts see rising demand from consumers seeking speed and privacy over traditional clinics. This shift makes GLP-1 weight loss treatment feel like online shopping.
Novo Nordisk's Wegovy pill recorded 18,410 U.S. prescriptions in its first full week after launch, surpassing other GLP-1 starts. Investors eye its edge over Eli Lilly in the competitive obesity market. Oral treatments offer needle-free flexibility for patients.
New research challenges fears of quick weight regain after stopping GLP-1 drugs like Ozempic and Wegovy. Real-world data reveals many patients sustain their losses. Experts say durability is possible without lifelong treatment.
Emilly Murray transformed from 22st 2lbs to a slim 9st using Mounjaro, conquering binge eating and food noise. After hitting a plateau at 11st, she boosted water intake to 2-3 liters daily and increased meat and fish consumption. This simple strategy reignited her weight loss toward her 10st goal.
